NAFLD and Liver Fibrosis in Obese Adolescents

Conditions:   Liver Fibrosis;   Liver Steatosis;   Weight Loss Intervention:   Procedure: laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB) Sponsor:   Tel-Aviv Sourasky Medical Center Completed
Source: - Category: Research Source Type: clinical trials

Related Links:

We begin by complimenting Wang et al. for their research into treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) after Roux-en-Y Gastric Bypass (RYGB) and Laparoscopic Sleeve Gastrectomy (LSG) through the analysis of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) values at different timepoints. This is a burgeoning field of research, as NAFLD rates continue to rise globally. Bariatric surgery has been proven in numerous studies to improve AST and ALT values after bariatric surgery (1).
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Letter to the Editor Source Type: research
Nonalcoholic Fatty Liver Disease (NAFLD) prevalence is rising worldwide, as a direct consequence of the obesity epidemic. Bariatric Surgery provides proven NAFLD amelioration, although questions remain if Roux-en-Y Gastric Bypass (RYGB) or Laparoscopic Sleeve Gastrectomy (LSG) is more effective. To answer this question, we conducted a Systematic review and meta-analysis exclusively comparing RYGB against LSG for amelioration of NAFLD using four separate criteria: ALT, AST, NAFLD activity score (NAS), and NAFLD fibrosis score (NFS).
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Review articles Source Type: research
Conclusions: Bariatric surgery appears to be capable of partially reversing the obesity-related epigenome. The identification of potential epigenetic biomarkers predictive for the success of bariatric surgery may open new doors to personalized therapy for severe obesity. Introduction Obesity is currently a huge healthcare problem, worldwide, and is a risk factor for several diseases such as type 2 diabetes (T2D), cardiovascular disease and cancer (1). As the prevalence of obesity reaches pandemic proportions, this metabolic disease is estimated to become the biggest cause of mortality in the near future (2). In fact,...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
AbstractIntroductionNonalcoholic fatty liver disease (NAFLD) is an epidemic in the obese population. Bariatric surgery is known to reverse multiple metabolic complications of obesity such as diabetes, dyslipidemia, and NAFLD, but the timing of liver changes has not been well described.Materials and MethodsThis was an IRB-approved, two-institutional prospective study. Bariatric patients received MRIs at baseline and after a pre-operative liquid diet. Liver biopsies were performed during surgery and if NAFLD positive, the patients received MRIs at 1, 3, and 6  months. Liver volumes and proton-density fat fraction (PDFF)...
Source: Surgical Endoscopy - Category: Surgery Source Type: research
AbstractBackgroundBariatric surgery gains attention as a potential treatment for non-alcoholic fatty liver disease (NAFLD). The present study aimed to evaluate improvement of NAFLD after the two most common bariatric procedures with validated non-invasive instruments.Material and MethodsN = 100 patients scheduled for laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB) were included. NAFLD was evaluated preoperatively and postoperatively with liver stiffness measurement by transient elastography and laboratory-based fibrosis scores. Clinical data included body mass index (BMI), total weight lo...
Source: Obesity Surgery - Category: Surgery Source Type: research
Sleeve gastrectomy, gastric bypass, gastric banding, and duodenal switch are the most common bariatric procedures performed worldwide. Ninety-five percent of bariatric operations are performed with minimally invasive laparoscopic technique. Perioperative morbidities and mortalities average around 5% and 0.2%, respectively. Long-term weight loss averages around 15% to 25% or about 80 to 100 lbs (40 –50 kg). Comorbidities, including type 2 diabetes, hypertension, dyslipidemia, sleep apnea, arthritis, gastroesophageal reflux disease, and nonalcoholic fatty liver disease, improve or resolve after bariatric surgery.
Source: Gastrointestinal Endoscopy Clinics of North America - Category: Gastroenterology Authors: Source Type: research
ConclusionsMRI including in-opposed-phase imaging of the liver can detect the quantitative decrease of fatty infiltration within the liver after bariatric surgery and thus could be a valuable tool to monitor NAFLD/NASH postoperatively.
Source: Obesity Surgery - Category: Surgery Source Type: research
Conclusions The prevalence of NAFLD among morbidly obese surgical patients was high, although this condition was not associated with increased risk for postoperative complications. Because of unexpected findings in intraoperative liver biopsies, the routine indication of liver biopsies in patients at high risk for liver disease should be discussed.
Source: Obesity Surgery - Category: Surgery Source Type: research
ABSTRACT: Morbid obesity is strongly associated with nonalcoholic fatty liver disease (NAFLD), which is one of the most common causes of chronic liver disease worldwide. The present best treatment for NAFLD and nonalcoholic steatohepatitis (NASH) is weight reduction through lifestyle modification. Because of frustrating inefficiency of such a therapeutic approach, bariatric surgery is increasingly performed in adolescents as an alternative option for weight reduction. Standards of care and consensus for indications are, however, scarce. We explore the indications and limitations of bariatric surgery in children with severe...
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Medical Position Paper Source Type: research
More News: Eating Disorders & Weight Management | Gastrectomy | Gastric Bypass | Gastroenterology | Laparoscopy | Liver | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Research | Urology & Nephrology